Chitosan-Prussian Blue Nanozyme Studies: Cellular and In Vivo Data for Hearing Loss

A research document detailing experimental results for a chitosan-Prussian blue nanozyme (CS-PB) designed for auditory protection. The data includes in vitro measurements of reactive oxygen species, apoptosis markers, and inflammatory cytokines in cochlear cells, and in vivo validation in a noise-induced hearing loss rat model. The dataset was authored by Yong Li and last updated on 2026-04-21.

Use Cases

• Analyze the efficacy of nanozymes in reducing reactive oxygen species based on ROS fluorescence intensity data.
• Study the modulation of apoptosis pathways based on protein expression levels of Bax, Cleaved-caspase-3, and Bcl-XL.
• Investigate anti-inflammatory mechanisms based on cytokine levels (TNF-α, IL-1β, IL-6) and TLR4/NF-κB pathway inhibition.
• Validate in vivo therapeutic effects based on pathway activation and cytokine reduction correlations in a rat model.

Strengths

• Includes specific quantitative results, such as a 37% reduction in ROS and apoptosis decreasing from 27.5% to 14.1%.
• Provides in vitro and in vivo validation, showing pathway inhibition (e.g., p-P65/P65 decreased by 54%) and strong correlation metrics (r = 0.87–0.89).
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data format is a DOC file (11.5 MB), which may require conversion for programmatic analysis.

Provenance

Source

figshare, author Yong Li.

Collection Method

Experimental data from cellular assays (HEI-OC1 cochlear cells) and animal models (noise-induced hearing loss rats).

Freshness

Last updated 2026-04-21 05:35:43; freshness should be verified.